This Trial Watch summarizes therapeutic targets and drug development for liver fibrosis in MASH, highlighting urgent needs.
Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of cirrhosis and hepatocellular carcinoma. Conditional FDA approvals for resmetirom and semaglutide followed positive histological responses in recent trials, but full approval requires evidence of reduced major adverse liver outcomes. No drug is approved for MASH cirrhosis, a clear unmet need. This Trial Watch summarizes drug development landscape and promising therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: